← Back to Clinical Trials
Recruiting NCT06346158

NCT06346158 Prediction of Propofol Effect-Site Concentration Associated With Deep Anesthesia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06346158
Status Recruiting
Phase
Sponsor Ciusss de L'Est de l'Île de Montréal
Condition Anesthesia
Study Type OBSERVATIONAL
Enrollment 110 participants
Start Date 2025-04-07
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Cognitive testingelectroencephalogramHigh density electroencephalogram

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 110 participants in total. It began in 2025-04-07 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to explore the variability of the concentration at the effect site (Ce) of propofol to reach deep anesthesia (DA) during induction of general anesthesia in adults. The investigators hypothesized that there is a great variability in this Ce that could be precisely explained by * Electroencephalographic (EEG) features available prior to induction of anesthesia * Cognitive performance * Patients characteristics Participants will undergo preoperative cognitive testing and awake EEG. Then, induction of general anesthesia will be performed using continuous infusion of propofol. The Ce at which Deep anesthesia is observed will be recorded.

Eligibility Criteria

Inclusion Criteria: * Scheduled for any kind of surgery under general anesthesia. * Adults Exclusion Criteria: * Inability to communicate in French or English, * Known allergy or intolerance or other medical condition that precludes the use of prescribed general anesthesia protocol for this study, * Patients requiring rapid sequence induction, * Anticipated or known difficult intubation patient, * Anticipated or known difficult ventilation patient, * Body mass index ≥ 35 kg.m-2.

Contact & Investigator

Central Contact

Louis Morisson, MD, MSc

✉ louis.morisson@umontreal.ca

📞 514-252-3400

Principal Investigator

Louis Morisson, MD, MSc

PRINCIPAL INVESTIGATOR

CIUSSS de l'Est de l'Ile de Montréal

Frequently Asked Questions

Who can join the NCT06346158 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06346158 currently recruiting?

Yes, NCT06346158 is actively recruiting participants. Contact the research team at louis.morisson@umontreal.ca for enrollment information.

Where is the NCT06346158 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT06346158 clinical trial?

NCT06346158 is sponsored by Ciusss de L'Est de l'Île de Montréal. The principal investigator is Louis Morisson, MD, MSc at CIUSSS de l'Est de l'Ile de Montréal. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology